This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Finerenone for chronic kidney disease in patients with type 2 diabetes mellitus

< Back

Finerenone for chronic kidney disease in patients with type 2 diabetes mellitus


Endocrine, Nutritional and Metabolic

February 2020

Finerenone is in clinical development for the treatment of chronic kidney disease in adults with type 2 diabetes mellitus. Diabetes is a condition that causes the blood sugar level to become too high. The majority of diabetes cases are type 2 diabetes, where the pancreas does not produce enough insulin or when the cells in the body do not respond properly to insulin. Diabetes is the leading cause of chronic kidney disease and failure in adults. People affected by chronic kidney disease have a reduced life expectancy and lower quality of life, as well as substantially increased risk of heart disease and adverse health outcomes.
Finerenone is selective inhibitor of a specific protein, which blocks the damaging effects of hormones (such as aldosterone and cortisol) which can cause damage to the heart and kidneys in diabetic patients. Finerenone is administered orally in tablet form, and evidence suggests it may offer organ protection compared to similar inhibitors which are currently used. If licensed, finerenone will offer patients with type 2 diabetes mellitus who have chronic kidney disease an add-on therapy to slow down long-term kidney damage and reduce the adverse impact on the structure and function of the heart and vessels.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts